Clinical Trial

A Study on the Bone-health Effectiveness of Applying Recombinant Factor VIII Fc (rFVIIIFc) to Patients With Hemophilia A (Prototype A)

Recruiting
View on ClinicalTrials.gov →
Summary
Study Objectives\* 1. Provide a systematic evaluation of the treatment outcomes in patients with hemophilia A 2. Emphasize the importance and clinical benefits of rFVIII-Fc in joint and bone health. 3. Compare the clinical outcomes from 1 year before and after switching to EHL. 4. Exploratory: Identify biomarkers that could provide more useful and convenient evaluations of joint and bone health. (Time-saving and easy to monitor)
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2023-07-31; most recent amendment 2024-04-08.
Trial Details
NCT Number NCT05981274
Lead Sponsor Tri-Service General Hospital (TSGH)
Conditions Severe Hemophilia A Without Inhibitor
Enrollment 45 participants
Start Date 2023-07-14
Primary Completion 2027-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-04-10